Overview


According to FutureWise analysis the market for exosome diagnostic and therapeutic in 2025 is US$ 0.68 billion, and is expected to reach US$ 3.91 billion by 2033 at a CAGR of 24.44%. The exosome market is rapidly growing due to their recognition as important biomarkers for early disease detection, particularly in cancer and neurodegenerative disorders. Innovations in exosome-based drug delivery systems are also advancing personalized medicine by offering targeted, less invasive treatments. As research continues to explore their potential, the market is set for significant expansion across diagnostics, therapeutics, and regenerative medicine.

Exosome diagnostics and therapeutics are emerging fields that hold great promise for transforming disease detection, monitoring, and treatment approaches. Exosomes are small extracellular vesicles secreted by cells, containing a variety of biological information, such as proteins, lipids, and nucleic acids. These vesicles are essential for intercellular communication and are involved in numerous physiological and pathological processes, including cancer, cardiovascular diseases, neurodegenerative disorders, and immune responses.

In the realm of diagnostics, researchers are investigating exosomes as potent biomarkers for the early detection of diseases and the monitoring of their progression. Since exosomes reflect the molecular composition of their parent cells, analyzing their cargo provides a non-invasive means to identify and diagnose diseases at an early stage, often prior to the onset of symptoms. This capability is especially valuable in oncology, where exosome-based liquid biopsy techniques are being developed to identify cancer-related mutations, track tumor evolution, and evaluate treatment responses using simple blood or urine samples.

On the therapeutic side, exosomes are being explored as potential vehicles for targeted drug delivery and gene therapy. Their inherent ability to transport bioactive molecules and interact with specific cells makes them ideal candidates for delivering therapeutic agents directly to diseased tissues, thereby minimizing off-target effects. This approach has the potential to enhance treatment efficacy for conditions such as cancer, neurological disorders, and autoimmune diseases. Additionally, exosomes are under investigation for their ability to modulate immune responses and facilitate tissue repair, positioning them as promising candidates in regenerative medicine.

The market for exosome diagnostics and therapeutics is witnessing significant growth, propelled by advances in biotechnology, a deeper understanding of exosome biology, and the rising demand for personalized medicine. As research progresses, exosomes are expected to play a pivotal role in reshaping both disease diagnosis and the development of targeted therapies.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Exosome Diagnostic and Therapeutic Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Exosome Diagnostic and Therapeutic Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Aethlon Medical, Inc
  • Therapeutic Solutions International, Inc
  • ReNeuron Group plc
  • Immune Therapy Holdings AB
  • Cell Guidance Systems LLC
  • BioRegenerative Sciences
  • Evomic Science LLC
  • NorgenBiotek Corp
  • Exosome Diagnostics, Inc./Bio-Techne
  • MiltenyiBiotec
  • NanoSomix Inc.
  • Thermo Fisher Scientific Inc.
  • Malvern Instruments Ltd.
  • System Biosciences Inc.
  • NX Pharmagen
  • Sistemic Inc.
  • Capricor Therapeutics
  • Exiqon A/S

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Application

  • Diagnostic
  • Therapeutic

By Product

  • Instruments
  • Reagents
  • Software

By End-User

  • Hospitals
  • Cancer Institutes
  • Diagnostic Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Exosome Diagnostic and Therapeutic Market By Application, By Product, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Application launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Exosome Diagnostic and Therapeutic Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Exosome Diagnostic and Therapeutic Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Exosome Diagnostic and Therapeutic Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Exosome Diagnostic and Therapeutic Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Diagnostic
        2. Therapeutic

  • 8.   Exosome Diagnostic and Therapeutic Market, By Product Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Instruments
        2. Reagents
        3. Software

  • 9.   Exosome Diagnostic and Therapeutic Market, By End-User Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Hospitals
        2. Cancer Institutes
        3. Diagnostic Centers
        4. Others

  • 10.   North America Exosome Diagnostic and Therapeutic Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 11.   Latin America Exosome Diagnostic and Therapeutic Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 12.   Europe Exosome Diagnostic and Therapeutic Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 13.   Asia Pacific Exosome Diagnostic and Therapeutic Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 14.   Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Aethlon Medical, Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Therapeutic Solutions International, Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. ReNeuron Group plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Immune Therapy Holdings AB
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Cell Guidance Systems LLC
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. BioRegenerative Sciences
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Evomic Science LLC
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. NorgenBiotek Corp
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Exosome Diagnostics, Inc./Bio-Techne
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. MiltenyiBiotec
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. NanoSomix Inc. (U.S.)
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Thermo Fisher Scientific Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Malvern Instruments Ltd.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. System Biosciences Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. NX Pharmagen
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Sistemic Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Capricor Therapeutics
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Exiqon A/S
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients